Drug Type Fc fusion protein |
Synonyms SRB 19, SRB19 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER3 antagonists(Receptor tyrosine-protein kinase erbB-3 antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | Switzerland | 01 Jun 2025 | |
Squamous Cell Carcinoma of Head and Neck | Preclinical | Chile | 10 Oct 2022 | |
Triple Negative Breast Cancer | Preclinical | Chile | 10 Oct 2022 |